BTIG Reiterates Buy on Cartesian Therapeutics, Maintains $44 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.0%

Neg 0% Neu 90% Pos 0%

BTIG analyst Julian Harrison reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $44 price target.

Comments

No comments yet. Be the first!